A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)
Ralph Benedict(University at Buffalo, State University of New York), Helmut Butzkeuven(Australian Regenerative Medicine Institute), Marisa McGinley(Cleveland Clinic), Owain W. Howell(Hammersmith Hospital), Licínio Craveiro(Roche (Switzerland)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Letizia Leocani(Vita-Salute San Raffaele University), Gıancarlo Comı(Vita-Salute San Raffaele University), Catherine Lubetzki(Centre National de la Recherche Scientifique), Maria Pia Sormani(University of Genoa), Robert A Bermel(Cleveland Clinic), Guy Gherardi(Roche (Sweden)), Pavan Bhargava(Johns Hopkins University), Amit Bar‐Or(McGill University), Thomas Kuenzel(Université de Bordeaux), Christine Lebrun‐Frénay(Université Côte d'Azur), Agne Kazlauskaite(Roche (Sweden)), Roland Henry(University of California System), Declan Chard(National Institute for Health and Care Research), Douglas L. Arnold(University of Oxford), Finn Sellebjerg(Danish Multiple Sclerosis Center)
Cited by 4
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k